MoA-Based Potency Bioassays for Immunotherapy Programs Targeting the TIGIT/CD112R/CD226 Axis
Part # PS423
Abstract
Here we show a portfolio of MOA-based bioassays for the TIGIT/CD112R/CD226 axis that can be used for antibody screening, characterization, potency and stability studies. These bioassays provide the following:
- Biologically relevant measurement of antibody MOA
- Consistent and reliable thaw-and-use format
- Easy implementation, rapid results
Printed in USA.